Xarelto approved to cut risk of major CV events in CAD/PAD patients
US regulators have approved Bayer/Janssen’s Xarelto to cut the risk of major cardiovascular (CV) events in people with chronic coronary or peripheral artery disease (CAD/PAD).
Until now, aspirin has been the standard of care for people with CAD and PAD, which affect 16.5 million and 10 million in the US, respectively, but research shows it is “simply not enough to address the underlying risk of blood clots that accompanies these conditions,” Janssen noted.
Xarelto, it says, is now the first and only Factor Xa inhibitor approved for patients living with these conditions.
Read more: http://www.pharmatimes.com/news/xarelto_approved_to_cut_risk_of_major_cv_events_in_cadpad_patients_1255527
Until now, aspirin has been the standard of care for people with CAD and PAD, which affect 16.5 million and 10 million in the US, respectively, but research shows it is “simply not enough to address the underlying risk of blood clots that accompanies these conditions,” Janssen noted.
Xarelto, it says, is now the first and only Factor Xa inhibitor approved for patients living with these conditions.
Read more: http://www.pharmatimes.com/news/xarelto_approved_to_cut_risk_of_major_cv_events_in_cadpad_patients_1255527